Longeveron Inc. (LGVN), a clinical stage biotechnology company, will be participating at the 149th annual conference of the National Investment Banking Association, to be held in Fort Lauderdale, FL, September 6-7, 2023.
The company will discuss about its pipeline progress and investment strategies at the conference.
Longeveron's lead drug candidate LOMECEL-B is in Phase 2a study in Alzheimer's disease, dubbed CLEAR MIND, with topline results expected by October 2023.
A Phase 2 study of LOMECEL-B in hypoplastic left heart syndrome, dubbed ELPIS II, is ongoing, with enrollment expected to be completed by mid-2024.
A Phase 2 study of Lomecel-B in patients with aging-related frailty has been initiated and enrolment is underway in Japan.
LGVN closed Wednesday's trading at $2.44, up 2.09%.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.